Addition of excess HCO 2 H to {2,5-Ph 2 -3,4-Tol 2 (η 5 -C 4 CO)]Ru(CO) 2 } 2 (6) at -20°C led to the formation of [2,5-Ph 2 -3,4-Tol 2 (η 5 -C 4 COH)]Ru(CO) 2 (η 1 -OCHO) (5), a proposed intermediate in catalytic transfer hydrogenations developed by Shvo. Hydroxycyclopentadienyl formate 5 undergoes rapid reversible dissociation of HCO 2 H at 20°C, and undergoes decarboxylation at 1°C to form a 1:10 mixture of {[2,5-Ph 2 -3,4-Tol 2 (η 5 -C 4 CO)] 2 H}Ru 2 (CO) 4 (µ-H) (3):[2,5-Ph 2 -3,4-Tol 2 (η 5 -C 4 COH)Ru(CO) 2 H] (4). 5 does not reduce PhCHO below the temperature at which 5 is converted to hydride 4. The catalytic production of benzyl alcohol from 5 and PhCHO in the presence of excess HCO 2 H is not accelerated by higher concentrations of PhCHO, indicating that 5 does not directly reduce PhCHO. Formate complex 5 is the precursor of hydride 4 which transfers hydrogen to PhCHO. A crucial role for the CpOH proton in the decarboxylation of 5 was indicated by the much slower decarboxylation of the methoxycyclopentadienyl analog [2,5-Ph 2 -3,4-Tol 2 (η 5 -C 4 COCH 3 )]Ru(CO) 2 (η 1 -OCHO) (7). A mechanism for decarboxylation of 5 is proposed which involves reversible dissociation of formic acid to form the unsaturated dienone dicarbonyl ruthenium intermediate C, followed by simultaneous transfer of hydride to ruthenium from the formic acid carbon and of proton to the carbonyl of C from the formic acid OH group.
No takes yet. Share an insight, caveat, or question.
Casey et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: